Pharming Group N.V. Financials
Pharming Group N.V. (PHAR) reported $376.1M in revenue for fiscal year 2025, up 26.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Pharming’s FY2025 rebound was driven by cash conversion and lighter leverage more than by headline earnings growth.
Between FY2023 and FY2025, operating cash flow swung from-$17.3M to$54.7M even though the income statement only moved back to a narrow profit. Because FY2025 net income was just$2.5M while cash rebuilt to$145.3M , the recovery appears to have come from working-capital release and non-cash charges as much as from cleaner underlying profitability.
The balance sheet remained liquid through the uneven years, with cash of
The business also looks light on maintenance capex but increasingly intangible-heavy: capital spending was only
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Pharming Group N.V.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Pharming Group N.V., and counted as zero in the overall score.
Pharming Group N.V.'s revenue surged 26.6% year-over-year to $376.1M, reflecting rapid business expansion. This strong growth earns a score of 85/100.
Pharming Group N.V. carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 84/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.59, Pharming Group N.V. holds $2.59 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
Pharming Group N.V. has a free cash flow margin of 14.3%, earning a moderate score of 49/100. The company generates positive cash flow after capital investments, but with room for improvement.
Not available for Pharming Group N.V., and counted as zero in the overall score.
Pharming Group N.V. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Pharming Group N.V. reported $2.5M of net income while generating $54.7M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.
Key Financial Metrics
Earnings & Revenue
Pharming Group N.V. generated $376.1M in revenue in fiscal year 2025. This represents an increase of 26.6% from the prior year.
Pharming Group N.V. reported $2.5M in net income in fiscal year 2025. This represents an increase of 121.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Pharming Group N.V. generated $54.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2187.4% from the prior year.
Pharming Group N.V. held $145.3M in cash against $14.4M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Pharming Group N.V.'s net profit margin was 0.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.7 percentage points from the prior year.
Pharming Group N.V.'s ROE was 0.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 6.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Pharming Group N.V. invested $749K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 5.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
PHAR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Revenue | $376.1M+26.6% | $297.2M+21.1% | $245.3M+19.3% | $205.6M+3.4% | $198.9M-6.3% | $212.2M+12.0% | $189.4M |
| Interest Expense | $1.0M-0.4% | $1.0M-4.6% | $1.1M+74.9% | $622K-21.8% | $795K+3.8% | $766K+3.2% | $742K |
| Income Tax | $10.3M+207.9% | $3.3M+328.8% | -$1.5M-211.5% | $1.3M-81.5% | $7.1M+11.6% | $6.3M-46.0% | $11.7M |
| Net Income | $2.5M+121.4% | -$11.8M-12.3% | -$10.5M-177.1% | $13.7M-14.5% | $16.0M-57.6% | $37.7M-6.9% | $40.6M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).
PHAR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $500.0M+25.0% | $400.0M-13.6% | $462.9M+8.7% | $425.8M+7.2% | $397.3M-5.1% | $418.5M+63.5% | $255.9M |
| Current Assets | $299.5M+7.6% | $278.4M-12.0% | $316.3M+14.0% | $277.5M+11.2% | $249.4M-5.2% | $263.2M+120.4% | $119.4M |
| Cash & Equivalents | $145.3M+164.5% | $54.9M-11.0% | $61.7M-70.2% | $207.3M+8.0% | $191.9M-6.5% | $205.2M+175.9% | $74.3M |
| Inventory | $64.9M+16.5% | $55.7M-1.8% | $56.8M+34.1% | $42.3M+55.0% | $27.3M+29.1% | $21.2M+30.4% | $16.2M |
| Accounts Receivable | $54.7M-0.2% | $54.8M+18.8% | $46.2M+67.1% | $27.6M-7.9% | $30.0M-16.5% | $35.9M+24.4% | $28.9M |
| Goodwill | $135.5M+122.1% | $61.0M-14.4% | $71.3M | N/A | N/A | N/A | N/A |
| Total Liabilities | $222.9M+24.6% | $178.9M-26.7% | $244.1M+10.4% | $221.2M+8.2% | $204.4M-13.0% | $235.0M+69.7% | $138.5M |
| Current Liabilities | $115.8M+56.9% | $73.8M-5.3% | $78.0M+30.6% | $59.7M+27.6% | $46.8M-39.1% | $76.8M-32.7% | $114.3M |
| Long-Term Debt | $14.4M-46.8% | $27.0M-8.6% | $29.5M-1.1% | $29.8M+61.7% | $18.5M+124.3% | $8.2M+68.2% | $4.9M |
| Total Equity | $277.1M+25.4% | $221.1M+1.0% | $218.8M+6.9% | $204.6M+6.1% | $192.9M+5.2% | $183.4M+56.3% | $117.4M |
| Retained Earnings | -$273.0M+0.9% | -$275.5M-3.9% | -$265.3M-3.4% | -$256.4M+6.1% | -$273.2M+7.6% | -$295.6M+13.2% | -$340.7M |
PHAR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $54.7M+3147.8% | -$1.8M+89.6% | -$17.3M-177.0% | $22.5M-40.7% | $37.8M-54.7% | $83.6M+12.8% | $74.1M |
| Capital Expenditures | $749K-5.2% | $790K-45.0% | $1.4M+4.4% | $1.4M-87.2% | $10.7M+130.6% | $4.7M+75.9% | $2.6M |
| Free Cash Flow | $54.0M+2187.4% | -$2.6M+86.2% | -$18.7M-188.9% | $21.1M-22.2% | $27.1M-65.7% | $79.0M+10.4% | $71.5M |
| Investing Cash Flow | $26.3M-17.0% | $31.6M+124.4% | -$129.4M-2530.7% | $5.3M+125.0% | -$21.3M-36.3% | -$15.6M+44.7% | -$28.3M |
| Financing Cash Flow | $1.5M+104.3% | -$34.4M-3212.0% | -$1.0M+79.1% | -$5.0M+82.2% | -$27.9M-146.1% | $60.7M+195.6% | -$63.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PHAR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Net Margin | 0.7%+4.7pp | -4.0%+0.3pp | -4.3%-10.9pp | 6.7%-1.4pp | 8.0%-9.8pp | 17.8%-3.6pp | 21.4% |
| Return on Equity | 0.9%+6.3pp | -5.4%-0.5pp | -4.8%-11.5pp | 6.7%-1.6pp | 8.3%-12.3pp | 20.6%-14.0pp | 34.5% |
| Return on Assets | 0.5%+3.5pp | -3.0%-0.7pp | -2.3%-5.5pp | 3.2%-0.8pp | 4.0%-5.0pp | 9.0%-6.8pp | 15.8% |
| Current Ratio | 2.59-1.2x | 3.77-0.3x | 4.06-0.6x | 4.65-0.7x | 5.33+1.9x | 3.43+2.4x | 1.05 |
| Debt-to-Equity | 0.05-0.1x | 0.120.0x | 0.130.0x | 0.15+0.1x | 0.10+0.1x | 0.040.0x | 0.04 |
| FCF Margin | 14.3%+15.2pp | -0.9%+6.8pp | -7.6%-17.9pp | 10.3%-3.4pp | 13.6%-23.6pp | 37.2%-0.5pp | 37.8% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Similar Companies
Where Pharming Group N.V. Ranks
Frequently Asked Questions
What is Pharming Group N.V.'s annual revenue?
Pharming Group N.V. (PHAR) reported $376.1M in total revenue for fiscal year 2025. This represents a 26.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Pharming Group N.V.'s revenue growing?
Pharming Group N.V. (PHAR) revenue grew by 26.6% year-over-year, from $297.2M to $376.1M in fiscal year 2025.
Is Pharming Group N.V. profitable?
Yes, Pharming Group N.V. (PHAR) reported a net income of $2.5M in fiscal year 2025, with a net profit margin of 0.7%.
How much debt does Pharming Group N.V. have?
As of fiscal year 2025, Pharming Group N.V. (PHAR) had $145.3M in cash and equivalents against $14.4M in long-term debt.
What is Pharming Group N.V.'s net profit margin?
Pharming Group N.V. (PHAR) had a net profit margin of 0.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Pharming Group N.V.'s return on equity (ROE)?
Pharming Group N.V. (PHAR) has a return on equity of 0.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pharming Group N.V.'s free cash flow?
Pharming Group N.V. (PHAR) generated $54.0M in free cash flow during fiscal year 2025. This represents a 2187.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pharming Group N.V.'s operating cash flow?
Pharming Group N.V. (PHAR) generated $54.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Pharming Group N.V.'s total assets?
Pharming Group N.V. (PHAR) had $500.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pharming Group N.V.'s capital expenditures?
Pharming Group N.V. (PHAR) invested $749K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Pharming Group N.V.'s current ratio?
Pharming Group N.V. (PHAR) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.
What is Pharming Group N.V.'s debt-to-equity ratio?
Pharming Group N.V. (PHAR) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pharming Group N.V.'s return on assets (ROA)?
Pharming Group N.V. (PHAR) had a return on assets of 0.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pharming Group N.V.'s Piotroski F-Score?
Pharming Group N.V. (PHAR) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pharming Group N.V.'s earnings high quality?
Pharming Group N.V. (PHAR) reported $2.5M of net income while generating $54.7M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Pharming Group N.V.?
Pharming Group N.V. (PHAR) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.